Group items tagged

The drug, 'durvalumab', can double the overall time someone can survive with an aggressive form of lung cancer from two-and-a-half to five years. It has been approved by the National Institute for Health and Care Excellence (NICE) and the NHS has sealed a deal with manufacturer AstraZeneca to begin rolling it out. The new treatment will be offered to more than 550 patients a year with advanced non-small-cell lung cancer (NSCLC) who have already undergone both chemotherapy and radiotherapy concurrently. NHS said: "The drug can stop the cancer from getting worse for more than two years - significantly longer than treatment with a combination of chemotherapy and radiotherapy, which can only hold the disease at bay for around six months. This increases overall survival time and gives patients more precious moments with their loved ones." Dame Cally Palmer, national cancer director for NHS England, said: "We are resolute in our ambition to fight the devastating effects of cancer and new pioneering treatments like durvalumab are a vital lifeline for people living with cancer - giving them more precious time with family and friends.

AstraZeneca said on Thursday (June 30) that a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery. Data showed the combination was more effective in removing cancer cells in tissue samples taken during surgery when compared with just chemotherapy in patients with non-small cell lung cancer, the drugmaker said. The interim result is a boost to the company's oncology efforts - a major area of focus - following disappointing data for Imfinzi earlier in the year in another area of therapy. AstraZeneca added the trial would continue as planned to assess the additional main goal of event-free survival, and the interim data would be shared with health authorities globally. Imfinzi belongs to the immunotherapy class of treatments, which boost the body's defences to fight cancer by using antibodies that block or bind to foreign substances in the body. The treatment generated $2.41 billion in 2021 sales.

'Tepotinib' has been recommended by the National Institute for Health and Care Excellence (NICE) to patients with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC). The new potentially life-extending drug is available from Thursday (14 April). It has been recommended for routine use across the NHS in England through Project Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster. NICE has published its final appraisal document recommending tepotinib (also known as Tepmetko and produced by company Merck Serono Ltd) as an option for treating advanced NSCLC with METex14 skipping gene alterations in adults. People with METex14 skipping alterations of NSCLC make up between 1-2% of all adults with lung cancer in England. Tepotinib, which requires people to take two tablets once daily, provides a new targeted treatment for adults with METex14 skipping gene alterations. Just over 700 people in England would be eligible to receive tepotinib as either a first or second-line treatment.

Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.

Thousands of lung cancer patients in England will benefit from a ground-breaking new drug that can reduce the risk of relapse. This follows a deal brokered by NHS England and approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for atezolizumab therapy to treat non-small cell lung cancer (NSCLC). More than 850 patients are expected to be eligible for the drug in the first year, rising to more than 1000 in the third year. It is the first immunotherapy approved for patients with early-stage NSCLC who have undergone surgery and chemotherapy. Clinical trials have shown that atezolizumab can reduce the risk of cancer relapse or death by 34 per cent in patients with early-stage NSCLC.

Breast cancer can be easily placed at the top of life threatening diseases in the world as it accounts for almost 26 % of all cancer cases in the world and it is the largest killer of people in the world after lungs cancer. Despite of the cruel facts about this type of cancer reasons, mechanisms and treatment of breast cancer are still shrouded and it can't be said for sure that what causes this cancer and what treatment options can be best used to get rid of it.

Note that the expressions of malignancy and cancer are also used to describe cancer. The benign tumor is not cancerous, and is less health. It can put pressure on an organ or tissue, but in a limited space and does not spread in the body. Prevalence

Congress signs comprehensive cancer legislation addressing high mortality cancer treatment.

Consult a well known cancer specialist to get the treatment. Being the Best Oncologist in Delhi NCR, Dr. Manish singhal is recommended for the same.

CCI is the best name in Consultant/Treatment For Lung Cancer In Noida, Delhi-Ncr, India with a promise of quality treatment services.

Patients with advanced non-small cell lung cancer (NSCLC) may soon be offered a blood test to assess their treatment options, instead of having to provide a tumour sample for analysis.

Consult a well known cancer specialist to get the treatment. Being the Best Oncologist in Delhi NCR, Dr. Manish singhal is recommended for the same.

There are many tests in the market to go for the detection but the two most opted ones are full-body CT scan and MRI. Cancer specialists in Delhi NCR can help you suggest the test to go for. Consult best cancer doctor in Delhi NCR

Consult a well known cancer specialist to get the treatment. Being the Best Oncologist in Delhi NCR, Dr. Manish singhal is recommended for the same.

Consult a well known cancer specialist to get the treatment. Being the Best Oncologist in Delhi NCR, Dr. Manish singhal is recommended for the same

Consult a well known cancer specialist to get the treatment. Being the Best Oncologist in Delhi NCR, Dr. Manish singhal is recommended for the same.

Consult a well known cancer specialist to get the treatment. Being the Best Oncologist in Delhi NCR, Dr. Manish singhal is recommended for the same.

Asbestos poisoning is a serious health concern that can have long-lasting effects on your well-being. Exposure to asbestos fibers can lead to various health issues, including lung cancer, mesothelioma, and asbestosis. If you suspect that you've been exposed to asbestos or are experiencing symptoms related to asbestos poisoning, it's crucial to take immediate action. 1. Recognize the Symptoms The first step in dealing with asbestos poisoning is to recognize the symptoms. Common signs of asbestos exposure include shortness of breath, persistent coughing, chest pain, and fatigue. Additionally, you may experience respiratory issues such as wheezing or difficulty breathing. Exploring the use of asbestos at Honeywell in Massachusetts can help you get a better understanding of the potential risks associated with asbestos exposure and the importance of taking proactive measures to protect yourself and your loved ones from its harmful effects. It's essential to pay attention to any changes in your health and seek medical attention if you suspect asbestos exposure.